Skip to Content


New Animal Drugs for Use in Animal Feeds; Change of Sponsor

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Food and Drug Administration, HHS.


Final rule.


The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for 10 new animal drug applications (NADAs) from Merial Ltd. to Huvepharma AD.


This rule is effective November 23, 2009.

Start Further Info


David R. Newkirk, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-276-8307, e-mail:

End Further Info End Preamble Start Supplemental Information


Merial Ltd., 3239 Satellite Blvd., Bldg. 500, Duluth, GA 30096-4640, has informed FDA that it has transferred ownership of, and all rights and interest in, the following 10 approved NADAs to Huvepharma AD, 33 James Boucher Blvd., Sophia 1407, Bulgaria: NADA 036-304, 049-179, 049-180, 118-507, 040-264, 041-541, 044-016, 046-209, 049-934, and 099-150. Accordingly, the agency is amending the regulations to reflect the transfer of ownership.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

Start List of Subjects

List of Subjects in 21 CFR Part 558

  • Animal drugs
  • Animal feeds
End List of Subjects Start Amendment Part

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is amended as follows:

End Amendment Part Start Part


End Part Start Amendment Part

1. The authority citation for 21 CFR part 558 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b, 371.

End Authority
Start Amendment Part

2. In § 558.55, in paragraph (d)(2)(iv), in the table, in the entry for “Carbarsone 227 to 340.5”, in the “Sponsor” column, remove “000006” and in its place add “016592”.

End Amendment Part Start Amendment Part

3. Amend § 558.58 as follows:

End Amendment Part

a. Remove paragraphs (a)(3), (b)(1), and (b)(2);

b. In paragraph (e)(1)(i), in the table, in the “Sponsor” column, remove “050604”;

c. In paragraphs (e)(1)(ii) and (e)(1)(iii), in the table, in the “Limitations” column, remove “050604” wherever it occurs and in its place add “016592”; and

d. Revise paragraph (b).

The revisions are to read as follows:

Amprolium and ethopabate.
* * * * *

(b) Approvals. See No. 016592 in § 510.600(c) of this chapter.

* * * * *
Start Amendment Part

4. In § 558.175, in paragraph (b) and in the table in paragraph (d), in the “Sponsor” column, remove “050604” wherever it occurs and in its place add “016592”.

End Amendment Part Start Signature
Start Printed Page 61029

Dated: November 16, 2009.

Steven D. Vaughn,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

End Signature End Supplemental Information

[FR Doc. E9-28009 Filed 11-20-09; 8:45 am]